The Research Council of Norway announced the grant for the project, Blood microRNAs for the early diagnosis of Alzheimer’s disease, which is conditional upon signature by the parties.
DiaGenic CEO Henrik Lund said Norwegian Research Council has in the past contributed with significant funding for DiaGenic’s development of diagnostic tests.
"This new grant for development of blood based diagnostics for early Alzheimer’s disease represents an important financial contribution," Lund added.
DiaGenic’s biobank and the HUNT Biosciences biobank will supply the clinical samples, the company said.